(S (NP (JJ Adverse) (NN drug) (NN reaction) (PRN (-LRB- -LRB-) (NP (NN ADR)) (-RRB- -RRB-))) (VP (VBZ is) (ADJP (RB widely) (JJ concerned) (PP (IN for) (NP (NML (JJ public) (NN health)) (NN issue))))) (. .))
(S (NP (NNS ADRs)) (VP (VBP are) (NP (NP (CD one)) (PP (IN of) (NP (JJS most) (JJ common) (NNS causes))) (S (VP (TO to) (VP (VB withdraw) (NP (DT some) (NNS drugs)) (PP (IN from) (NP (NN market)))))))) (. .))
(S (NP (NML (NN Prescription) (NN event)) (NN monitoring) (PRN (-LRB- -LRB-) (NP (NN PEM)) (-RRB- -RRB-))) (VP (VBZ is) (NP (DT an) (JJ important) (NN approach) (S (VP (TO to) (VP (VB detect) (NP (DT the) (JJ adverse) (NN drug) (NNS reactions))))))) (. .))
(S (NP (DT The) (JJ main) (NN problem) (S (VP (TO to) (VP (VB deal) (PP (IN with) (NP (DT this) (NN method))))))) (VP (VBZ is) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (ADVP (RB automatically)) (VP (VB extract) (NP (NP (DT the) (JJ medical) (NNS events)) (CC or) (NP (NN side) (NNS effects))) (PP (IN from) (NP (NP (NML (JJ high) (HYPH -) (NN throughput)) (JJ medical) (NNS events)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBN collected) (PP (IN from) (NP (NN day))) (PP (IN to) (NP (NN day) (JJ clinical) (NN practice)))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (JJ novel) (NN concept)) (PP (IN of) (NP (NN feature) (NN matrix)))) (S (VP (TO to) (VP (VB detect) (NP (DT the) (NNS ADRs)))))) (. .))
(S (NP (NP (NN Feature) (NN matrix)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN extracted) (PP (IN from) (NP (JJ big) (JJ medical) (NNS data))) (PP (IN from) (NP (DT The) (NML (NNP Health) (NNP Improvement) (NNP Network) (PRN (-LRB- -LRB-) (ADJP (JJ THIN)) (-RRB- -RRB-))) (NN database))))))) (, ,)) (VP (VBZ is) (VP (VBN created) (S (VP (TO to) (VP (VB characterize) (NP (DT the) (JJ medical) (NNS events)) (PP (IN for) (NP (NP (DT the) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBP take) (NP (NNS drugs)))))))))))) (. .))
(S (NP (NN Feature) (NN matrix)) (VP (VBZ builds) (NP (NP (DT the) (NN foundation)) (PP (IN for) (NP (DT the) (ADJP (JJ irregular) (CC and) (JJ big)) (JJ medical) (NNS data))))) (. .))
(S (ADVP (RB Then)) (NP (NN feature) (NN selection) (NNS methods)) (VP (VBP are) (VP (VBN performed) (PP (IN on) (NP (NN feature) (NN matrix))) (S (VP (TO to) (VP (VB detect) (NP (DT the) (JJ significant) (NNS features))))))) (. .))
(S (ADVP (RB Finally)) (NP (DT the) (NNS ADRs)) (VP (MD can) (VP (VB be) (VP (VBN located) (PP (VBN based) (PP (IN on) (NP (DT the) (JJ significant) (NNS features))))))) (. .))
(S (NP (DT The) (NNS experiments)) (VP (VBP are) (VP (VBN carried) (PRT (RP out)) (PP (IN on) (NP (NP (CD three) (NNS drugs)) (: :) (NP (NN Atorvastatin) (, ,) (NNP Alendronate) (, ,) (CC and) (NNP Metoclopramide)))))) (. .))
(S (S (NP (NP (JJ Major) (NN side) (NNS effects)) (PP (IN for) (NP (DT each) (NN drug)))) (VP (VBP are) (VP (VBN detected)))) (CC and) (S (NP (JJR better) (NN performance)) (VP (VBZ is) (VP (VBN achieved) (PP (VBN compared) (PP (IN to) (NP (JJ other) (JJ computerized) (NNS methods))))))) (. .))
(S (S (NP (DT The) (VBN detected) (NNS ADRs)) (VP (VBP are) (VP (VBN based) (PP (IN on) (NP (JJ computerized) (NNS methods)))))) (, ,) (NP (JJ further) (NN investigation)) (VP (VBZ is) (VP (VBN needed))) (. .))
